GPP
DYN icon

Great Point Partners’s Dyne Therapeutics DYN Stock Holding History

Great Point Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-845,000
Closed -$10M – 34
2021
Q4 		$10M Buy
845,000
+100,000
+13% +$1.41M 2.23% 21
2021
Q3 		$12.1M Buy
745,000
+72,441
+11% +$1.28M 2.82% 15
2021
Q2 		$14.2M Buy
+672,559
New +$12.6M 2.97% 14

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners's DYN Position: Q1 2022 in Review

Great Point Partners sold out of Dyne Therapeutics (DYN) in Q1 2022, closing a stake of 845,000 shares — an estimated $10M sold.

Great Point Partners first reported a position in DYN in Q2 2021 and held it in 3 quarters. The position peaked at $14.2M in Q2 2021. 94 funds tracked by Wall St. Rank hold DYN as of Q1 2022.

  • Great Point Partners reported no remaining Dyne Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Great Point Partners sold 845,000 Dyne Therapeutics shares in Q1 2022, an estimated $10M.
  • Great Point Partners first reported a position in Dyne Therapeutics in Q2 2021 and held it in 3 quarters.
  • Great Point Partners's Dyne Therapeutics position peaked at $14.2M in Q2 2021.
  • 94 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2022.

Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.